[go: up one dir, main page]

MA38390B1 - Composés tétrahydropyrrolothiazines - Google Patents

Composés tétrahydropyrrolothiazines

Info

Publication number
MA38390B1
MA38390B1 MA38390A MA38390A MA38390B1 MA 38390 B1 MA38390 B1 MA 38390B1 MA 38390 A MA38390 A MA 38390A MA 38390 A MA38390 A MA 38390A MA 38390 B1 MA38390 B1 MA 38390B1
Authority
MA
Morocco
Prior art keywords
tetrahydropyrrolothiazine
compounds
tetrahydropyrrolothiazine compounds
compound
formula
Prior art date
Application number
MA38390A
Other languages
English (en)
Other versions
MA38390A1 (fr
Inventor
Steven James Green
Dustin James Mergott
Brian Morgan Watson
Jr Leonard Larry Winneroski
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA38390A1 publication Critical patent/MA38390A1/fr
Publication of MA38390B1 publication Critical patent/MA38390B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne un composé de formule (i), dans laquelle r est h ou f ; et a est : (a), (b), (c) ou (d) ; ou un sel pharmaceutiquement acceptable de celui-ci.
MA38390A 2013-03-12 2014-03-04 Composés tétrahydropyrrolothiazines MA38390B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361776819P 2013-03-12 2013-03-12
PCT/US2014/020070 WO2014143579A1 (fr) 2013-03-12 2014-03-04 Composés tétrahydropyrrolothiazines

Publications (2)

Publication Number Publication Date
MA38390A1 MA38390A1 (fr) 2018-08-31
MA38390B1 true MA38390B1 (fr) 2020-01-31

Family

ID=50382615

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38390A MA38390B1 (fr) 2013-03-12 2014-03-04 Composés tétrahydropyrrolothiazines

Country Status (37)

Country Link
US (3) US8841293B1 (fr)
EP (1) EP2970336B1 (fr)
JP (1) JP6095844B2 (fr)
KR (1) KR101688761B1 (fr)
CN (1) CN105026404B (fr)
AP (1) AP2015008713A0 (fr)
AR (1) AR094918A1 (fr)
BR (1) BR112015018738A8 (fr)
CA (1) CA2898500C (fr)
CL (1) CL2015002529A1 (fr)
CR (1) CR20150418A (fr)
CY (1) CY1119585T1 (fr)
DK (1) DK2970336T3 (fr)
EA (1) EA026006B1 (fr)
ES (1) ES2653421T3 (fr)
HR (1) HRP20171851T1 (fr)
HU (1) HUE037487T2 (fr)
IL (1) IL240903B (fr)
JO (1) JO3317B1 (fr)
LT (1) LT2970336T (fr)
MA (1) MA38390B1 (fr)
ME (1) ME02910B (fr)
MX (1) MX2015012628A (fr)
MY (1) MY180083A (fr)
NO (1) NO3039297T3 (fr)
NZ (1) NZ712207A (fr)
PE (1) PE20151542A1 (fr)
PH (1) PH12015502031B1 (fr)
PL (1) PL2970336T3 (fr)
PT (1) PT2970336T (fr)
RS (1) RS56645B1 (fr)
SG (1) SG11201507499XA (fr)
SI (1) SI2970336T1 (fr)
TN (1) TN2015000340A1 (fr)
TW (1) TWI593692B (fr)
UA (1) UA112941C2 (fr)
WO (1) WO2014143579A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA37756B1 (fr) 2012-06-13 2018-09-28 Hoffmann La Roche Nouveaux composés diazaspirocycloalcane et azaspirocycloalcane
SI2900669T1 (sl) 2012-09-25 2019-12-31 F. Hoffmann-La Roche Ag Derivati heksahidropirolo(3,4-C)pirola in sorodne spojine kot zaviralci avtotaksina (ATX) in kot zaviralci tvorbe lizofosfatidne kisline (LPA) za zdravljenje npr. bolezni ledvic
CA2886507C (fr) 2012-10-26 2016-09-20 Eli Lilly And Company Inhibiteurs de bace
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
UA118201C2 (uk) 2013-11-26 2018-12-10 Ф. Хоффманн-Ля Рош Аг НОВИЙ ОКТАГІДРОЦИКЛОБУТА[1,2-c;3,4-c']ДИПІРОЛ-2-ІЛ
TWI684452B (zh) 2014-03-14 2020-02-11 美國禮來大藥廠 胺基噻嗪化合物
EA032357B1 (ru) 2014-03-26 2019-05-31 Ф. Хоффманн-Ля Рош Аг Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
CA2937616A1 (fr) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Composes bicycliques en tant qu'inhibiteurs de production d'autotaxine (atx) et d'acide lysophosphatidique (lpa)
TWI570127B (zh) * 2014-09-15 2017-02-11 美國禮來大藥廠 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物
TWI599358B (zh) * 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
AR103406A1 (es) * 2015-01-30 2017-05-10 Lilly Co Eli Sal de tosilato
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
AR104241A1 (es) 2015-04-29 2017-07-05 Lilly Co Eli Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
PE20180479A1 (es) 2015-09-04 2018-03-07 Hoffmann La Roche Nuevos derivados de fenoximetilo
AU2016328535A1 (en) 2015-09-24 2017-11-09 F. Hoffmann-La Roche Ag Bicyclic compounds as ATX inhibitors
EP3353178B1 (fr) 2015-09-24 2021-07-14 F. Hoffmann-La Roche AG Composés bicycliques comme inhibiteurs mixtes de atx/ca
JP6845230B2 (ja) 2015-09-24 2021-03-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ デュアルａｔｘ／ｃａ阻害剤としての新規な二環式化合物
EP3353176B1 (fr) 2015-09-24 2022-01-19 F. Hoffmann-La Roche AG Composes bicycliques utiles comme inhibiteurs atx
TW201740954A (zh) 2016-03-16 2017-12-01 美國禮來大藥廠 組合療法
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
WO2018112094A1 (fr) 2016-12-15 2018-06-21 Amgen Inc. Dérivés de dioxyde de 1,4-thiazine et de dioxyde de 1,2,4-thiadiazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation
CA3047286A1 (fr) 2016-12-15 2018-06-21 Amgen Inc. Derives d'oxazine en tant qu'inhibiteurs de beta-secretase et procedes d'utilisation
AU2017376444B2 (en) 2016-12-15 2021-09-30 Amgen Inc. Thiazine derivatives as beta-secretase inhibitors and methods of use
MA54101A (fr) * 2016-12-15 2021-10-27 Amgen Inc Dérivés de thiazine et d'oxazine bicycliques en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation
MX386618B (es) 2016-12-15 2025-03-19 Amgen Inc Derivados de tiazina condensados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso.
JP7090099B2 (ja) 2017-03-16 2022-06-23 エフ．ホフマン－ラ ロシュ アーゲー Ａｔｘインヒビターとしての新規二環式化合物
CN110392679B (zh) 2017-03-16 2023-04-07 豪夫迈·罗氏有限公司 可用作双重atx/ca抑制剂的杂环化合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
AU2003219955A1 (en) * 2002-03-22 2003-10-13 Eli Lilly And Company Isoquinoline-3-carboxylic acid derivatives as excitatory amino acid receptor antagonists
AU2006259572A1 (en) * 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
EP1942105B8 (fr) 2005-10-25 2014-08-13 Shionogi&Co., Ltd. Derive aminodihydrothiazine
WO2008133273A1 (fr) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. Composition pharmaceutique pour le traitement de la maladie d'alzheimer
CN101910143B (zh) 2008-01-18 2013-08-21 卫材R&D管理有限公司 稠合的氨基二氢噻嗪衍生物
KR20110003347A (ko) * 2008-04-22 2011-01-11 쉐링 코포레이션 Ｂａｃｅ-1 억제제로서의 페닐-치환된 2-이미노-3-메틸 피롤로 피리미디논 화합물, 조성물 및 이의 용도
TWI431004B (zh) * 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
CN102119161B (zh) 2008-06-13 2015-07-08 盐野义制药株式会社 具有β分泌酶抑制作用的含硫杂环衍生物
CA2738150A1 (fr) 2008-09-30 2010-04-08 Eisai R&D Management Co., Ltd. Derive d'aminodihydrothiazine fusionne inedit
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
JPWO2011071109A1 (ja) 2009-12-11 2013-04-22 塩野義製薬株式会社 アミノ基を有する縮合ヘテロ環化合物
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
WO2012162334A1 (fr) 2011-05-24 2012-11-29 Bristol-Myers Squibb Company Composés destinés à la réduction de la production de bêta-amyloïdes
JO3143B1 (ar) * 2012-04-03 2017-09-20 Lilly Co Eli مركبات تتراهيدرو بيرولو ثيازين

Also Published As

Publication number Publication date
EA026006B1 (ru) 2017-02-28
PL2970336T3 (pl) 2018-03-30
CA2898500C (fr) 2017-11-14
CY1119585T1 (el) 2018-03-07
CA2898500A1 (fr) 2014-09-18
HRP20171851T1 (hr) 2018-01-12
MY180083A (en) 2020-11-20
CR20150418A (es) 2015-09-16
EP2970336B1 (fr) 2017-10-04
CN105026404A (zh) 2015-11-04
ES2653421T3 (es) 2018-02-07
KR20150119070A (ko) 2015-10-23
JO3317B1 (ar) 2019-03-13
UA112941C2 (uk) 2016-11-10
IL240903B (en) 2018-12-31
IL240903A0 (en) 2015-10-29
LT2970336T (lt) 2018-01-10
US20140350245A1 (en) 2014-11-27
US8987254B2 (en) 2015-03-24
TWI593692B (zh) 2017-08-01
JP6095844B2 (ja) 2017-03-15
PE20151542A1 (es) 2015-10-28
WO2014143579A1 (fr) 2014-09-18
TW201520217A (zh) 2015-06-01
NO3039297T3 (fr) 2018-03-10
KR101688761B1 (ko) 2016-12-21
PH12015502031A1 (en) 2016-01-18
HK1212694A1 (en) 2016-06-17
DK2970336T3 (da) 2017-11-13
BR112015018738A2 (pt) 2017-07-18
CL2015002529A1 (es) 2016-03-28
PH12015502031B1 (en) 2016-01-18
HUE037487T2 (hu) 2018-08-28
MA38390A1 (fr) 2018-08-31
RS56645B1 (sr) 2018-03-30
SG11201507499XA (en) 2015-10-29
AR094918A1 (es) 2015-09-09
CN105026404B (zh) 2016-11-23
AP2015008713A0 (en) 2015-09-30
US8841293B1 (en) 2014-09-23
US20150157641A1 (en) 2015-06-11
US20140275044A1 (en) 2014-09-18
ME02910B (fr) 2018-04-20
PT2970336T (pt) 2017-12-21
EA201591491A1 (ru) 2016-01-29
EP2970336A1 (fr) 2016-01-20
JP2016512252A (ja) 2016-04-25
MX2015012628A (es) 2016-07-07
TN2015000340A1 (en) 2017-01-03
AU2014228351A1 (en) 2015-09-17
SI2970336T1 (sl) 2017-11-30
NZ712207A (en) 2019-09-27
BR112015018738A8 (pt) 2018-01-23

Similar Documents

Publication Publication Date Title
MA38390A1 (fr) Composés tétrahydropyrrolothiazines
MA52948B1 (fr) Composés
MA38472A1 (fr) Composé peptidique
EA201591503A1 (ru) Производные нафтиридина, полезные в качестве антагонистов альфа-v-бета-6 интегрина
BR112017006253A2 (pt) novos compostos
MA46337B1 (fr) Composé de pyridine
EA201690172A1 (ru) Полиморф ингибиторов syk
MA38583A1 (fr) Dérivés de dolastatine 10 et d'auristatines
EA201792021A1 (ru) Ингибитор jak
MA38645A1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
MA40302B1 (fr) Dérivés de carbazole
MA37686A1 (fr) Composés phénoxyéthyl pipéridine
MA37501B1 (fr) Composés de pyrazole utilisés en tant qu'inhibiteurs de sglt1
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
MX2015017156A (es) Inhibidores de bace.
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2
MX2021012440A (es) Farmacos precursores de oxabicicloheptanos.
MA44781B1 (fr) Composé hétérocyclique condensé
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain
MA39305A3 (fr) Dérivés d'éthynyle
EA201690924A1 (ru) Фторфенилпиразольные соединения
MA38857A1 (fr) Dérivés de 1-(pipérazin-1-yl)-2-([1,2,4]triazol-1-yl)-éthanone
MA43231B1 (fr) Bloqueur des canaux sodiques
MA38991B1 (fr) Dérivés d'indole-urée substitués par un glucopyranosyle et leur utilisation à titre d'inhibiteurs de sglt